Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor
{{output}}
The small-molecule drug ralimetinib was developed as an inhibitor of the p38α mitogen-activated protein kinase, and it has advanced to phase 2 clinical trials in oncology. Here, we demonstrate that ralimetinib resembles EGFR-targeting drugs in pharmacogenomic... ...
